MedTrace Logo

Evaluation of Point-of-Care (EPOC) for COVID-19

NCT05227404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2024-12-06

Study results available
· View outcomes & findings →

Summary

EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.

Conditions

Interventions

DIAGNOSTIC_TEST

LumiraDX

Point-of-care test for SARS-CoV-2

DIAGNOSTIC_TEST

RightSign

Point-of-care test for SARS-CoV-2

DIAGNOSTIC_TEST

Case Control

Genscript assay performed on the plasma sample

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2022-09-02
Completion
2022-09-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227404 on ClinicalTrials.gov